Mirikizumab (Omvoh)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses mirikizumab (Omvoh), 300 mg/15 mL, solution for IV infusion after dilution in a vial and mirikizumab (Omvoh), 100 mg/1 mL, 200 mg/2 mL, solution for SC injection in a prefilled pen or syringe.
• Indication: For the treatment of adult patients with moderately to severely active Crohn disease who have had an inadequate response, loss of response, or intolerance to conventional therapy or a biologic treatment